See more : Lifeline Biotechnologies, Inc. (LLBO) Income Statement Analysis – Financial Results
Complete financial analysis of Collegium Pharmaceutical, Inc. (COLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Collegium Pharmaceutical, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Graines Voltz S.A. (GRVO.PA) Income Statement Analysis – Financial Results
- Bareket Capital Ltd (BRKT.TA) Income Statement Analysis – Financial Results
- Hokkoku Financial Holdings, Inc. (7381.T) Income Statement Analysis – Financial Results
- BFF Bank S.p.A. (BFF.MI) Income Statement Analysis – Financial Results
- Hammer Metals Limited (HMX.AX) Income Statement Analysis – Financial Results
Collegium Pharmaceutical, Inc. (COLL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.collegiumpharma.com
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 566.77M | 463.93M | 276.87M | 310.02M | 296.70M | 280.41M | 28.48M | 1.71M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 240.60M | 254.45M | 126.25M | 130.18M | 193.66M | 165.68M | 2.60M | 213.00K | 171.00K | 0.00 | 0.00 |
| Gross Profit | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.50M | -171.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 57.55% | 45.15% | 54.40% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.98M | 14.96M | 14.16M |
| General & Administrative | 151.80M | 160.44M | 114.77M | 108.46M | 0.00 | 0.00 | 0.00 | 0.00 | 18.93M | 2.71M | 1.89M |
| Selling & Marketing | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | 0.00 | 0.00 | 0.00 |
| SG&A | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -94.00K | -348.00K | 0.00 | 0.00 |
| Operating Expenses | 159.21M | 176.17M | 128.41M | 123.60M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.67M | 16.04M |
| Cost & Expenses | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.10M | 103.92M | 95.79M | 26.91M | 17.67M | 16.04M |
| Interest Income | 15.62M | 1.05M | 12.00K | 232.00K | 1.94M | 1.69M | 582.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.34M | 63.21M | 21.01M | 28.88M | 909.00K | 20.13M | 582.00K | 94.00K | 439.00K | 252.00K | 76.00K |
| Depreciation & Amortization | 149.26M | 134.39M | 68.94M | 61.61M | 15.80M | 110.91M | 594.00K | 655.00K | 171.00K | 187.00K | 169.00K |
| EBITDA | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.65M | -17.48M | -15.95M |
| EBITDA Ratio | 54.40% | 7.41% | 8.02% | 18.21% | -7.35% | -6.78% | -262.86% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Operating Income | 166.96M | -104.57M | -46.70M | -5.09M | -23.75M | -20.69M | -75.45M | -94.08M | -26.91M | -17.67M | -16.04M |
| Operating Income Ratio | 29.46% | -22.54% | -16.87% | -1.64% | -8.00% | -7.38% | -264.95% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -91.23M | -62.17M | -21.00M | -28.65M | 1.03M | -18.44M | 582.00K | -94.00K | -348.00K | -252.00K | -155.00K |
| Income Before Tax | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Income Before Tax Ratio | 13.36% | -6.22% | -1.22% | 8.90% | -7.66% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 27.58M | -3.85M | -74.89M | 830.00K | -14.57M | -110.91M | -1.16M | 94.00K | -91.00K | 252.00K | 79.00K |
| Net Income | 48.16M | -25.00M | 71.52M | 26.75M | -8.15M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Net Income Ratio | 8.50% | -5.39% | 25.83% | 8.63% | -2.75% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| EPS | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| EPS Diluted | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| Weighted Avg Shares Out | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Weighted Avg Shares Out (Dil) | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications Joe Ciaffoni - President and CEO Colleen Tupper - CFO Scott Dreyer -...
Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results
STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30...
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
COLL or ZTS: Which Is the Better Value Stock Right Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
Why Collegium Pharmaceutical's Shares Are Trading Higher Today
Collegium Pharmaceutical Inc (NASDAQ: COLL) updated financial guidance for FY22 to include the expected impact of the BioDelivery Sciences International Inc (BDSI) acquisition. "Near-term, we are laser-focused on seamless integration of BDSI, maximizing the potential of.
COLL or ZTS: Which Is the Better Value Stock Right Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
New Strong Buy Stocks for March 3rd
ACGL, ACLS, COLL, SAH, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2022.
Collegium Pharmaceutical (COLL) Reports Q4 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -170.19% and 66.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports